Compare SWZ & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWZ | IBIO |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.6M | 84.6M |
| IPO Year | N/A | 2009 |
| Metric | SWZ | IBIO |
|---|---|---|
| Price | $5.90 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 68.1K | ★ 970.4K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | ★ 73.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.84 | $0.56 |
| 52 Week High | $9.43 | $4.86 |
| Indicator | SWZ | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 36.94 |
| Support Level | $5.88 | $2.02 |
| Resistance Level | $6.10 | $2.82 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 14.29 | 9.70 |
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.